Navigation Links
Universal Health Services, Inc. Reports 2007 Fourth Quarter and Full Year Earnings and 2008 Guidance
Date:2/28/2008

f the Board of Directors, Chief Executive Officer and President to The College of William & Mary ("W&M Funding").

After adjusting for the items discussed above applicable to each period presented, as indicated on the attached Supplemental Schedules, our adjusted net income during the three-month period ended December 31, 2007 was $39.6 million, or $.74 per diluted share, as compared to $32.4 million, or $.60 per diluted share, during the fourth quarter of 2006. Our adjusted net income during the year ended December 31, 2007 was $164.3 million, or $3.07 per diluted share, as compared to $157.3 million, or $2.79 per diluted share, during the prior year.

Net revenues increased 12% to $1.19 billion during the fourth quarter of 2007 as compared to $1.07 billion during the fourth quarter of 2006. Net revenues increased 13% to $4.75 billion during the year ended December 31, 2007 as compared to $4.19 billion during the prior year. Our consolidated operating margin, as calculated on the attached Supplemental Schedules (without adjusting for the various items mentioned above), was 12.9% and 12.3% during the three-month periods ended December 31, 2007 and 2006, respectively, and 13.1% during each of the years ended December 31, 2007 and 2006.

Acute Care Services:

At our acute care hospitals owned during both periods ("same facility basis"), inpatient admissions were unchanged and patient days decreased 1.4% during the fourth quarter of 2007 as compared to the fourth quarter of 2006. On a same facility basis, net revenues at our acute care facilities increased 7.6% during the fourth quarter of 2007 as compared to the comparable prior year quarter. Net revenue per adjusted admission at these facilities increased 4.8% during the fourth quarter of 2007 over the comparable prior year quarter. The operating margin at our acute care hospitals owned during both periods increased to 13.9% during the fourth quarter of 2007 as compared to 12.1% during the fou
'/>"/>

SOURCE Universal Health Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Families Rejoice in CDCs Advisory Committee on Immunization Practices Vote for Universal Childhood Influenza Vaccination
2. NJ Voters Take Heed: Be Wary of Presidential Candidates Touting Universal Healthcare
3. NutraCea Files Universal Shelf Registration Statement
4. Universal Health Services, Inc. Announces Dividend
5. Universal Health Services, Inc. Announces Share Repurchase Authorization
6. Internists diagnose health-care system ills, show how to achieve universal coverage
7. Internists Diagnose Health Care System Ills, Prescribe Remedies to Achieve Universal Coverage, Better Quality, and Lower Costs
8. Universal Health Services, Inc. Announces Dividend
9. Forum Highlights Role of Private Sector in Achieving Universal Health Coverage in Europe
10. Universal Health Services, Inc. Reports 2007 Third Quarter Earnings
11. New report: private/public insurance mix is most practical way to achieve universal coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... can be reduced by enabling patients to see the ... This is just one of several recommendations made in ... University of Bristol. , Called ,Primary care factors and ... report has been compiled by researchers from the University,s ... from studies around the world. They found that patients ...
(Date:7/24/2014)... to nicotine, known as neonicotinoids, were found commonly ... new USGS study. This is the first broad-scale ... States and one of the first conducted within ... broad range of insect pests, use of neonicotinoid ... across the United States, particularly in the Midwest. ...
(Date:7/24/2014)... Becker's Hospital Review has published the 2014 ... With Great Oncology Programs." Organizations on this year's list ... care, cancer outcomes and research. , The Becker's Hospital ... rankings and awards they have received from a variety ... part of the criteria for inclusion on the list: ...
(Date:7/24/2014)... 24, 2014 The European Omega 3 & ... & structured lipids market in Europe with analysis and forecast ... $670.37 million in 2012 to $989.91 million by 2018, at ... through the TOC of the European omega 3 & structured ... analysis provided. This also provides a glimpse of the segmentation ...
(Date:7/24/2014)... July 24, 2014 The European air and ... in 2014, and is expected to register a CAGR of ... Germany, Russia, and turkey are the major spenders in the ... medium extended air defense program and multinational (MEADS) program, which ... Browse through the TOC of the Europe air and missile ...
Breaking Medicine News(10 mins):Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4
... Physical Activity, Weight Control, and Breast Cancer Risk , ... randomized controlled trials that test the impact of physical ... There are substantial observational data suggesting that regular physical ... a reduction in breast cancer risk: however, it is ...
... concerned workers, navigating quarantine barriers and liabilities are ... epidemic-wary managersNEW YORK, April 28 Business managers ... government advisories should prepare to handle difficult legal ... pandemic scenario, says New York litigation partner Kenneth ...
... Acetaminophen, NSAIDs can cause liver or stomach illness ... 28 (HealthDay News) -- Many over-the-counter painkillers and ... on the potential danger of liver damage and ... Manufacturers will have to include these warnings on ...
... a statement of Debra L. Ness, President National Partnership for ... able to quickly bring the swine flu outbreak under control ... But that will happen more quickly if people can follow ... are trying to contain this potential pandemic. Unfortunately, in ...
... DATATRAK International, Inc. (Nasdaq: DATA ), ... solutions for the clinical trials industry, today reported that ... the newest member of the DATATRAK CRO Connect Program(TM). ... CROs, CPI is able to expand its electronic data ...
... State today issued an alert recommending that American citizens ... due to a recent outbreak of Swine Flu. While ... evolve, InsureMyTrip.com is reminding travelers of the ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO )"Right ...
Cached Medicine News:Health News:JNCI April 28 tip sheet 2Health News:JNCI April 28 tip sheet 3Health News:JNCI April 28 tip sheet 4Health News:Swine Flu Plans Triggering Difficult Legal Questions, Says Noted Pillsbury Attorney 2Health News:Swine Flu Plans Triggering Difficult Legal Questions, Says Noted Pillsbury Attorney 3Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:Stay Home with Swine Flu Symptoms? Not Without Paid Sick Days 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 3Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 4Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 2Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 3Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 4Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 5Health News:InsureMyTrip.com Informs Travelers of Insurance Companies Response to Swine Flu 6
(Date:7/24/2014)... -- , Revenues from continuing operations of $1.9 ... EPS from continuing operations of $1.08, up 1.9% versus  prior ... $0.92, 7% below prior year , Cash from operations ... Full year 2014 revenues now expected to be up 2.5% ... Full year 2014 adjusted diluted EPS range narrowed to  $4.00 ...
(Date:7/24/2014)... July 24, 2014 HIGHLIGHTS:Q2 2014 Results ... , Reported sales increased 3% to $701 million.  Sales ... rates added one percentage point to sales growth. , ... 6% in Applied and 1% in SAFC Commercial. , ... 2013, an increase of 13%.  Adjusted diluted EPS in Q2 ...
(Date:7/24/2014)... --  ndd Medical Technologies , a leader in innovative ... announced that its EasyOne Pro ® has been ... Capacity (DLCO) for phase 2 of the COPDGene ® ... Pulmonary Disease (COPD) ever undertaken.  COPD is now the ... affects millions of people worldwide.  In ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... and Company (NYSE: LLY ) announced that ... Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution ... study objective to restore testosterone levels to the normal ... testosterone. In addition, secondary outcomes showed that the treatment ...
... Wis., June 28, 2011 Novelos Therapeutics, Inc. ... for treatment and diagnosis of cancer, today announced that ... the defendants, motion to dismiss the putative federal securities ... Court for the District of Massachusetts in March 2010 ...
Cached Medicine Technology:Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 2Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 3Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 4Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 5Newly Published Study Showed Axiron® (testosterone) Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men 6Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 2Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit 3
Fiber optic illumination with XHL xenon halogen illumination. Large-diameter glass viewing window with 3X magnification, airtight window seal and swivelling viewing window....
Compact format, fiber optic illumination for uniform reflection-free light. Polycarbonate housing with chrome-plated cone....
Sleek, all-metal head with large-diameter viewing window. 3X magnification....
Provides bright output and rotating lens with ultra-seal for pneumatic otoscopy....
Medicine Products: